Progression-Free Survival: Helpful Biomarker or Clinically Meaningless End Point?
- 1 January 2015
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (1), 4-6
- https://doi.org/10.1200/jco.2014.57.9557
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System DatabaseJournal of Clinical Oncology, 2015
- Resampling the N9741 Trial to Compare Tumor Dynamic Versus Conventional End Points in Randomized Phase II TrialsJournal of Clinical Oncology, 2015
- Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal CancerJournal of Clinical Oncology, 2013
- Tumor Burden Modeling Versus Progression-Free Survival for Phase II Decision MakingClinical Cancer Research, 2013
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialThe Lancet Oncology, 2013
- Comparison of Continuous versus Categorical Tumor Measurement–Based Metrics to Predict Overall Survival in Cancer Treatment TrialsClinical Cancer Research, 2011
- Tumor Status at 12 Weeks Predicts Survival in Advanced Colorectal Cancer: Findings from NCCTG N9741The Oncologist, 2011
- Toward Efficient Trials in Colorectal Cancer: The ARCAD Clinical Trials ProgramJournal of Clinical Oncology, 2010
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor DynamicsJournal of Clinical Oncology, 2009
- Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup TrialJournal of Clinical Oncology, 2006